Updated:
Grifols
Grifols, founded in 1909 by Dr. Josep Antoni Grifols i Roig in Barcelona, is a global plasma and biopharma company generating €1.7B in Q1 2026 revenue.
Grifols
Grifols traces its roots to 1909, when Dr. Josep Antoni Grifols i Roig founded a clinical analysis laboratory in Barcelona, the precursor to Laboratorios Grifols. The company grew under Víctor Grífols i Lucas, who led it for six decades and was honored by the Barcelona City Council with a street naming at its institutional headquarters. The firm operates across plasma-derived medicines, diagnostics, and transfusion medicine, with an integrated model spanning plasma collection centers, pharmaceutical production, and sales. Grifols' portfolio includes more than 2,300 offices in 30 countries as of 2022. It invests in R&D for rare and chronic diseases, leveraging its plasma expertise. The company does not disclose a typical AUM figure as it is a publicly traded healthcare corporation, not an asset manager. Grifols employs over 23,000 people globally. In Q1 2026, the firm reported €1.7B in revenue and €73 million net profit (per the firm, May 2026). It also doubled positions in its Spanish vocational training program in May 2026. Grifols is recognized in the Dow Jones Best-in-Class sustainability score. A key structural differentiator is its vertical integration in plasma — from donor collection through fractionation to final product. This gives Grifols control over the full supply chain, a rare model in biopharma. The company also maintains a separate philanthropic and ethical focus through its Donors and Communication channels.
General information
Firm type
other
Year founded
1909
AUM
Undisclosed
Location
Region
Europe
Country
Spain
City
Barcelona
Corporate office
Barcelona, Spain
Principals
Víctor Grífols i Lucas
Pioneer and heart of Grifols (deceased)
Dr. Josep Antoni Grifols i Roig
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at Grifols?
Grifols is a publicly traded company led by an executive management team, not a single family office. Investment decisions are overseen by the Board of Directors and executive leadership, which historically includes members of the Grífols family. Specific individuals holding investment authority are not publicly listed in the same way as a private investment firm.
How does Grifols source proprietary deal flow?
Grifols sources its business through internal R&D and strategic acquisitions in the biopharma and diagnostics space. Its vertical integration in plasma gives it unique access to plasma supply and processing capabilities, which can lead to proprietary product development and partnerships. The firm does not disclose a typical venture capital-style deal flow mechanism.
Is Grifols structured as a single family office or does it operate more like a venture firm?
Grifols is a publicly traded multinational corporation (healthcare), not a family office or venture firm. It operates as a biopharmaceutical company with a legacy of family involvement, but its capital allocation is managed by a corporate board and management team, not a dedicated family office entity.
What investment stages does Grifols typically target?
Grifols invests primarily in R&D and manufacturing expansion within its existing therapeutic areas, such as plasma-derived medicines and diagnostics. It does not typically engage in early-stage venture investments or external fund commitments. The firm's focus is on internal innovation and scaling its own product pipeline.
Which sectors does Grifols explicitly avoid?
Grifols does not publicly state any explicit sectors it avoids. However, its operations are concentrated on plasma and biopharma, so it does not participate in unrelated industries like technology, real estate, or consumer goods. Its investment focus is solely on healthcare and life sciences.
How is Grifols related to other family-controlled entities?
The Grífols family has historically controlled the company through a public float of shares with a family stake. There is no publicly disclosed separate family office entity; the family's wealth is tied to the company's performance. The firm's website does not mention any other family-controlled vehicles.
Where does the underlying wealth come from?
The Grífols family wealth originated from the founding and operation of the Grifols company, which was established in 1909. The company's growth in plasma-derived medicines and diagnostics generated the family fortune. No separate wealth origin for a family office is disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: